
Laia Domingo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9297851/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cost-Effectiveness and Harm-Benefit Analyses of Risk-Based Screening Strategies for Breast Cancer. PLoS ONE, 2014, 9, e86858.	2.5	113
2	A systematic review and quality assessment of individualised breast cancer risk prediction models. British Journal of Cancer, 2019, 121, 76-85.	6.4	89
3	Tumor phenotype and breast density in distinct categories of interval cancer: results of population-based mammography screening in Spain. Breast Cancer Research, 2014, 16, R3.	5.0	60
4	Phenotypic characterization and risk factors for interval breast cancers in a population-based breast cancer screening program in Barcelona, Spain. Cancer Causes and Control, 2010, 21, 1155-1164.	1.8	58
5	Breast cancer risk after diagnosis by screening mammography of nonproliferative or proliferative benign breast disease: a study from a population-based screening program. Breast Cancer Research and Treatment, 2015, 149, 237-244.	2.5	57
6	Cross-national comparison of screening mammography accuracy measures in U.S., Norway, and Spain. European Radiology, 2016, 26, 2520-2528.	4.5	47
7	Prevalence and associated factors of intestinal parasitisation: a cross-sectional study among outpatients with gastrointestinal symptoms in Catalonia, Spain. Parasitology Research, 2011, 108, 87-93.	1.6	46
8	Aggressiveness features and outcomes of true interval cancers. European Journal of Cancer Prevention, 2013, 22, 21-28.	1.3	39
9	Personalized breast cancer screening strategies: A systematic review and quality assessment. PLoS ONE, 2019, 14, e0226352.	2.5	38
10	Mammographic and clinical characteristics of different phenotypes of screen-detected and interval breast cancers in a nationwide screening program. Breast Cancer Research and Treatment, 2015, 154, 403-415.	2.5	36
11	Risk of Breast Cancer in Women with False-Positive Results according to Mammographic Features. Radiology, 2016, 280, 379-386.	7.3	33
12	Differences in radiological patterns, tumour characteristics and diagnostic precision between digital mammography and screen-film mammography in four breast cancer screening programmes in Spain. European Radiology, 2011, 21, 2020-2028.	4.5	32
13	Mammographic breast density: How it affects performance indicators in screening programmes?. European Journal of Radiology, 2019, 110, 81-87.	2.6	29
14	Impact of Risk Factors on Different Interval Cancer Subtypes in a Population-Based Breast Cancer Screening Programme. PLoS ONE, 2014, 9, e110207.	2.5	24
15	Detection methods predict differences in biology and survival in breast cancer patients. BMC Cancer, 2012, 12, 604.	2.6	20
16	Does digital mammography suppose an advance in early diagnosis? Trends in performance indicators 6Âyears after digitalization. European Radiology, 2015, 25, 850-859.	4.5	17
17	Seventeen-years overview of breast cancer inside and outside screening in Denmark. Acta Oncológica, 2013, 52, 48-56.	1.8	16
18	Prevalence of persistent pain after breast cancer treatment by detection mode among participants in population-based screening programs. BMC Cancer, 2016, 16, 735.	2.6	14

Laia Domingo

#	Article	IF	CITATIONS
19	Changes in mammographic density over time and the risk of breast cancer: An observational cohort study. Breast, 2019, 46, 108-115.	2.2	14
20	Cumulative risk of breast cancer screening outcomes according to the presence of previous benign breast disease and family history of breast cancer: supporting personalised screening. British Journal of Cancer, 2017, 116, 1480-1485.	6.4	13
21	Biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case–control study. Cancer Medicine, 2017, 6, 1482-1489.	2.8	13
22	Gene Expression Profiling in True Interval Breast Cancer Reveals Overactivation of the mTOR Signaling Pathway. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 288-299.	2.5	10
23	Survival and Disease-Free Survival by Breast Density and Phenotype in Interval Breast Cancers. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 908-916.	2.5	9
24	Impact of COVID-19 on Hospital Admissions and Healthcare Quality Indicators in Non-COVID Patients: A Retrospective Study of the First COVID-19 Year in a University Hospital in Spain. Journal of Clinical Medicine, 2022, 11, 1752.	2.4	9
25	Developing and validating an individualized breast cancer risk prediction model for women attending breast cancer screening. PLoS ONE, 2021, 16, e0248930.	2.5	7
26	Clinical and radiological features of breast tumors according to history of false-positive results in mammography screening. Cancer Epidemiology, 2013, 37, 660-665.	1.9	4
27	Investigación en cribado de cáncer de mama: camino hacia estrategias personalizadas y decisiones compartidas. Revista De Senologia Y Patologia Mamaria, 2014, 27, 176-182.	0.1	3
28	Impact of adjuvant chemotherapy on the survival of patients with breast cancer diagnosed by screening. Cancer Medicine, 2019, 8, 6662-6670.	2.8	3
29	Factors associated with readmissions in women participating in screening programs and treated for breast cancer: a retrospective cohort study. BMC Health Services Research, 2019, 19, 940.	2.2	3
30	External validation of the PREDICT tool in Spanish women with breast cancer participating in populationâ€based screening programmes. Journal of Evaluation in Clinical Practice, 2019, 25, 873-880.	1.8	3
31	Evaluation of the effectiveness of hip and knee implant models used in Catalonia: a protocol for a prospective registry-based study. Journal of Orthopaedic Surgery and Research, 2019, 14, 61.	2.3	2
32	Exploring the Role of Breast Density on Cancer Prognosis among Women Attending Population-Based Screening Programmes. Journal of Oncology, 2019, 2019, 1-8.	1.3	2
33	Impact of Detection Mode in a Large Cohort of Women Taking Part in a Breast Screening Program. The Journal of Breast Health, 2022, 18, 182-189.	1.0	2
34	Use of health services among long-term breast cancer survivors in Spain: longitudinal study based on real-world data. Journal of Cancer Survivorship, 2022, 16, 132-141.	2.9	1
35	Readmissions and complications in breast ductal carcinoma in situ: A retrospective study comparing screen- and non-screen-detected patients. Women's Health, 2020, 16, 174550652096589.	1.5	0
36	Influence of surgical technique on complications, readmissions and clinical progress of breast cancer in women participating in screening programs. Revista De Senologia Y Patologia Mamaria, 2022, 35, 33-41.	0.1	0

#	Article	IF	CITATIONS
37	Dissemination of health technologies: Trends in the use of diagnostic test in breast cancer screening. Journal of Healthcare Quality Research, 2019, 34, 177-184.	0.6	0